DRAGAN CICIC - 20 Jun 2024 Form 3 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Role
SVP, Chief Development Officer
Signature
/s/ Dragan Cicic
Issuer symbol
SLS
Transactions as of
20 Jun 2024
Net transactions value
$0
Form type
3
Filing time
27 Jun 2024, 16:10:06 UTC
Next filing
05 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLS Common Stock 118,584 20 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLS Stock Option (Right to Buy) 20 Jun 2024 Common Stock 35,000 $1.89 Direct F2
holding SLS Stock Option (Right to Buy) 20 Jun 2024 Common Stock 47,250 $8.00 Direct F3
holding SLS Stock Option (Right to Buy) 20 Jun 2024 Common Stock 48,750 $5.34 Direct F4
holding SLS Stock Option (Right to Buy) 20 Jun 2024 Common Stock 55,000 $3.34 Direct F5
holding SLS Stock Option (Right to Buy) 20 Jun 2024 Common Stock 65,000 $0.5195 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 28,116 shares of Common Stock and (ii) 90,468 restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25,000 RSUs shall vest upon the satisfaction of performance-based vesting requirements, and 65,468 RSUs shall vest in one-quarter (1/4) increments annually on December 1 of each year provided that the Reporting Person remains in service with the Issuer through each such annual vesting date.
F2 One-quarter (1/4) of the option shares vested and became exercisable one year from the March 12, 2020 grant date, and the remainder vested and became exercisable in equal monthly installments for thirty-six (36) months thereafter.
F3 One-quarter (1/4) of the option shares vested and became exercisable one year from the March 4, 2021 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
F4 One-quarter (1/4) of the option shares vested and became exercisable one year from the January 31, 2022 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
F5 One-quarter (1/4) of the option shares vested and became exercisable one year from the February 2, 2023 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
F6 One-quarter (1/4) of the option shares will vest and become exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney